Patients with colorectal cancer may soon be able to rely on a blood test that detects tumor DNA to help determine the most effective treatment plan, according to a new study published last week in Nature Medicine. Advisory Board's Lindsey Paul discusses what the widespread adoption of liquid biopsies in treatment and disease monitoring may mean moving forward.